8:00 - 19:00

Working hours MON. - FRI.

 

News

Exclusive: Navalny affair no grounds to cancel Nord Stream pipeline, new German CDU chief says By Reuters

By Andreas Rinke BERLIN (Reuters) - Germany should not drop support for the planned Nord Stream 2 pipeline from Russia over the crackdown on Kremlin critic Alexei Navalny, as "feel-good moralising" is not foreign policy, the man best placed to be the next German chancellor told Reuters. Pointing to U.S. purchases of crude oil from Russia, Armin Laschet described himself as a...

Continue reading

Dow Futures Up 150 Pts; Payrolls Report in Focus By Investing.com

By Peter Nurse    Investing.com - U.S. stocks are seen trading higher Friday, continuing a four-day winning streak ahead of the closely-watched monthly jobs report. At 7:10 AM ET (1210 GMT), the Dow Futures contract was up 150 points, or 0.5%, S&P 500 Futures traded 20 points, or 0.5%, higher, and Nasdaq 100 Futures climbed 48 points, or 0.4%.  The major indices on Wall...

Continue reading

UK company directors face personal liability for financial statements – sources By Reuters

By Huw Jones LONDON (Reuters) - Company directors would become personally liable for the accuracy of their financial statements under landmark proposals from Britain's finance ministry next week to improve corporate behaviour, sources familiar with the plans said on Friday. Directors would have to vouch for the accuracy of financial statements in a version of the Sarbanes-Oxley regime introduced in the United...

Continue reading

FTSE 100 ekes out gains in cautious trade ahead of NFP By Investing.com

By Samuel Indyk Investing.com – The FTSE 100 trades with slight gains heading towards the North American crossover with financials leading the way higher. News flow has been relatively quiet although comments from the Bank of England Deputy Governor Ben Broadbent have garnered attention. Following the Bank of England decision yesterday, markets are pricing out the prospect of negative interest rates in the...

Continue reading

Analysis-Europe in battle to overcome economic lag vs US, Asia By Reuters

By Dhara Ranasinghe LONDON (Reuters) - Europe's slow vaccine roll-out means its economic recovery could lag behind upturns in the United States and Asia unless it can get the programme back on track in the weeks ahead. The International Monetary Fund last month hailed the strong China rebound and forecast that the U.S. and Japanese economies would return to pre-pandemic levels by...

Continue reading

Scottish court says case seeking clarification about independence vote premature By Reuters

LONDON (Reuters) - Scotland's top civil court has dismissed a case which sought a ruling that the Scottish parliament could hold an independence referendum without permission from London, saying it was premature and hypothetical. Independence campaigner Martin Keatings wanted legal backing for his argument the Scottish parliament had the authority to hold a new vote on secession without the explicit approval...

Continue reading

UK regulators say extra AstraZeneca vaccine data highlights efficacy in elderly By Reuters

LONDON (Reuters) - British regulators have received extra trial data from AstraZeneca (NASDAQ:AZN) that supports their view that the COVID-19 vaccine developed with Oxford University is effective in the elderly, a vaccines official said on Friday Britain has been rolling out the shot among all age groups after the Medicines and Healthcare products Regulatory Agency (MHRA) was the first regulator to approve...

Continue reading

UK regulator says data from Pfizer, AstraZeneca vaccine rollout confirms safety By Reuters

LONDON (Reuters) - Britain's medicine regulator on Friday said that data from the first weeks of the rollout of Pfizer (NYSE:PFE) and AstraZeneca (NASDAQ:AZN) COVID-19 vaccines confirmed their good safety profiles, saying both shots met strict regulatory standards. "The data we have collected provides further reassurance that the COVID-19 vaccines are safe and continue to meet the rigorous regulatory standards...

Continue reading

Regeneron Pharma Earnings, Revenue beat in Q4 By Investing.com

Regeneron Pharma (NASDAQ:REGN) reported on Friday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations. Regeneron Pharma announced earnings per share of $9.53 on revenue of $2.42B. Analysts polled by Investing.com anticipated EPS of $8.23 on revenue of $2.41B. Regeneron Pharma shares are up 3.26% from the beginning of the year and are trading at $498.84...

Continue reading
en_GBEnglish